Market Closed -
Nasdaq
04:00:00 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
0.8248
USD
|
+2.46%
|
|
+3.16%
|
-71.85%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
564.3
|
104.6
|
25.86
|
119.3
|
33.94
|
-
|
-
|
Enterprise Value (EV)
1 |
411.7
|
20.55
|
-48.31
|
119.3
|
-10.16
|
-55.56
|
-98.26
|
P/E ratio
|
-4.93
x
|
-2.46
x
|
-0.56
x
|
-2.36
x
|
-0.7
x
|
-0.82
x
|
-0.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
11.8
x
|
10.7
x
|
13.6
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
11.8
x
|
-3.21
x
|
-22.2
x
|
-
|
EV / EBITDA
|
-14,011,550
x
|
-489,413
x
|
1,023,258
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-14,918,977
x
|
-571,431
x
|
1,158,691
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
0.94
x
|
-0.17
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
23,214
|
23,463
|
23,560
|
40,711
|
41,153
|
-
|
-
|
Reference price
2 |
24.31
|
4.460
|
1.097
|
2.930
|
0.8248
|
0.8248
|
0.8248
|
Announcement Date
|
3/22/21
|
3/14/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
10.09
|
3.162
|
2.5
|
-
|
EBITDA
|
-29.38
|
-42
|
-47.21
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.42
|
-42.07
|
-47.28
|
-51.99
|
-50.56
|
-59.59
|
-70.91
|
Operating Margin
|
-
|
-
|
-
|
-515.34%
|
-1,598.78%
|
-2,383.6%
|
-
|
Earnings before Tax (EBT)
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-49.69
|
-60.7
|
-73.77
|
Net income
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-49.85
|
-60.4
|
-70.98
|
Net margin
|
-
|
-
|
-
|
-474.96%
|
-1,576.51%
|
-2,415.95%
|
-
|
EPS
2 |
-4.930
|
-1.810
|
-1.960
|
-1.240
|
-1.178
|
-1.012
|
-0.9775
|
Free Cash Flow
|
-27.59
|
-35.97
|
-41.69
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/21
|
3/14/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.964
|
2.165
|
3.073
|
2.887
|
2.002
|
2.875
|
2.875
|
2.875
|
EBITDA
|
-9.115
|
-
|
-11.87
|
-11.54
|
-12.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.135
|
-11.73
|
-11.88
|
-11.56
|
-12.11
|
-13.2
|
-13.97
|
-13.66
|
-11.16
|
-12.63
|
-12.7
|
-12.58
|
-15.37
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-672.05%
|
-645.36%
|
-444.45%
|
-386.7%
|
-631.02%
|
-441.86%
|
-437.66%
|
-534.66%
|
Earnings before Tax (EBT)
1 |
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-11.62
|
-10.86
|
-10.82
|
-16.46
|
Net income
1 |
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-11.62
|
-11.48
|
-11.51
|
-14.71
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-651.27%
|
-592.33%
|
-402.02%
|
-344.65%
|
-580.67%
|
-399.26%
|
-400.51%
|
-511.82%
|
EPS
2 |
-0.3900
|
-0.5000
|
-0.5100
|
-0.4800
|
-0.4700
|
-0.4000
|
-0.3200
|
-0.3000
|
-0.2300
|
-0.2800
|
-0.2900
|
-0.2767
|
-0.3300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/14/22
|
5/11/22
|
8/10/22
|
11/10/22
|
3/16/23
|
5/15/23
|
8/14/23
|
11/13/23
|
3/13/24
|
5/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
153
|
84.1
|
74.2
|
-
|
44.1
|
89.5
|
132
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-27.6
|
-36
|
-41.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
4.740
|
-6.350
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-4.590
|
-1.540
|
-1.770
|
-
|
-
|
-
|
-
|
Capex
|
0.07
|
0.09
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/21
|
3/14/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
0.8248
USD Average target price
2.75
USD Spread / Average Target +233.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -71.85% | 33.94M | | +29.03% | 49.18B | | -0.10% | 42.11B | | +48.26% | 40.37B | | -5.26% | 28.85B | | +11.48% | 26.09B | | -22.74% | 18.71B | | +9.06% | 13.26B | | +30.01% | 12.32B | | -1.51% | 11.99B |
Other Biotechnology & Medical Research
|